Mass drug administration (MDA) means once-in-a-year administration of Diethyl Carbamazine (DEC) tablet to all people (excluding children under 2 years, pregnant women and severely ill persons) in identified endemic areas. It aims at cessation of transmission of Lymphatic Filariasis. To study the coverage and compliance of MDA in Satna district during the campaign in June 2013. Cross-sectional observational study. Setting: Urban And Rural Areas In Satna District Identified As Endemic For Filariasis Where MDA 2013 Was Undertaken. Study Variables: Exploratory - Rural and urban clusters of Satna district; Outcome - coverage, compliance, actual coverage, side effects. Four clusters, each comprising 30 households from the Satna endemic district, yielded an eligible population of 650 (95.87%) of total 678. The coverage was 586 (90.15% out of eligible population) with variation across different areas. The compliance with drug ingestion was 88.05% with a gap of 11.95% to be targeted by intensive IEC. The effective coverage (79.38%) was below the target (85%). Side effects of DEC were minimum, transient and drug-specific. Overall coverage was marginally better in rural areas. The causes of poor coverage and compliance have been discussed and relevant suggestions have been made.​

A rapid and sensitive ultra-performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) method was developed and validated for the estimation of 17-desacetyl norgestimate in human plasma using solid-phase extraction technique. 17-desacetyl norgestimate D6 was used as the internal standard. Simple gradient chromatographic conditions and mass spectrometric detection enabled accurate and precise measurement of 17-desacetyl norgestimate at sub-picogram levels. The proposed method was validated for a linear range of 20–5000 pg/mL with a correlation coefficient Z 0.9988. The intra-run and inter-run precision and accuracy were within 10%. The overall recoveries for 17-desacetyl norgestimate and 17-desacetyl norgestimate D6 were 96.30%and 93.90%, respectively. The total run time was 4.5 min. The developed method was applied for the determination of the pharmacokinetic parameters of 17-desacetyl norgestimate following a single oral administration of a norgestimate and ethinyl estradiol 0.250 mg/0.035 mg tablets in 35 healthy female volunteers.